BCTG Acquisition Corp.

Status: Deal Closed
U=S
IPO Proceeds, $M $166.75M
IPO Date Sep 3, 2020
CEO Aaron I. Davis
Left Lead SVB Securities
IPO Cash in Trust 100.0%
SPAC Tenor 24 months
IPO Sector Healthcare

Biotechnology in North America and Europe

IPO Geography Global
Target Company Tango Therapeutics
Deal Announced Apr 14, 2021
Deal Size, $M $352.75M
Deal Sector Healthcare
Deal Geography US/Canada
SEC Filings www.sec.gov
Approval Vote Aug 9, 2021
Amendment Vote TBD
Closing Date Aug 10, 2021
Formerly BCTG TNGX

Sign up for Free Trial

No credit card required

Sign in for more on BCTG Acquisition Corp.:

  • Structure and cap table
  • 9 directors & officers
  • 17 filings and events
  • 1 underwriters
  • 7 deal advisors
  • 2 legal advisors
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Aaron I. Davis 42 Chairman and CEO
Christopher Fuglesang, Ph.D., J.D. 52 President and Director
Michael Beauchamp 30 CFO and Treasurer
Andrew Ellis, M.D., J.D. 37 Director
Carole L. Neuchterlein, J.D. 59 Director
Richard Heyman, Ph.D. 62 Director
Charles M. Baum, M.D., Ph.D. 62 Director
Jamie G. Christensen, Ph.D. 52 Director
James B. Avery Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
SVB Securities BR 14,500,000 units
14,500,000 units
Up-Front UW fee 2.00 %
Deferred UW fee 3.50 %

Sign in to view more advisor data.

Deal

Sign in to view merger details and deal financials.

Filings

Sign in to view 17 filings.

Shareholders

Sign in to view shareholders 13F filing data.